PMA device
aura6000 system
LivaNova USA, Inc. · Stimulator, Hypoglossal Nerve, Implanted, Apnea (MNQ, Class III) · First FDA decision Mar 18, 2026, newest Jun 18, 2026Sleep apnea
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
3
Naming "aura6000"
MAUDE reports
0
Brand "aura6000", since 2015
PubMed studies
1
Mentioning "aura6000"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing aura6000 system
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 3 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38387Wellpoint FederalUpdated Jul 14, 2026
- Hypoglossal Nerve Stimulation for Obstructive Sleep ApneaLocal determinationIn effectL38276Palmetto GBAUpdated May 8, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38528WPS Insurance CorporationUpdated Mar 20, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38307CGS Administrators, LLCUpdated Feb 27, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38310Noridian Healthcare Solutions, LLCUpdated Oct 16, 2025
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38398First Coast Service Options, Inc.Updated Jan 24, 2020
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38385Novitas Solutions, Inc.Updated Jan 24, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "aura6000", any status and sponsor, newest update first.
- Targeted Hypoglossal Neurostimulation Study #3Pivotal-lookingCompleted
ImThera Medical, Inc.Not on our public-company list
NCT02263859 · 138 participants · Start Feb 2015 · Primary completion Jun 2019
Device: aura6000 System · For: Obstructive Sleep Apnea
Sites: Chula Vista, California; Los Angeles, California; San Diego, California · 20 sites in all
ImThera Medical, Inc.Not on our public-company list
NCT01532180 · 14 participants · Start Nov 2009 · Primary completion Dec 2011
Device: aura6000 System · For: Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Respiration Disorders and 2 more
Sites: Brussels, Belgium
ImThera Medical, Inc.Not on our public-company list
NCT01796925 · 57 participants · Start Feb 2013 · Primary completion Sep 2013
Device: aura6000 THN System · For: Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Respiration Disorders and 2 more
Sites: San Diego, California; Denver, Colorado; Chicago, Illinois · 9 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "aura6000", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MNQ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "aura6000"[tiab]. The summary above synthesizes these.
- Targeted hypoglossal neurostimulation for obstructive sleep apnoea: a 1-year pilot study.
Mwenge GB, Rombaux P, Dury M, et al. · Eur Respir J · 2013Clinical Trial, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MNQ.
- Inspire II Upper Airway StimulatorInspire Medical Systems · PMA 2026
- Inspire® Upper Airway StimulationInspire Medical Systems · PMA 2025
- Genio® System 2.1Nyxoah S.A. · PMA 2025
- Inspire UAS High AHI/High BMIInspire Medical Systems · PMA 2023
- SleepSync ProgrammerInspire Medical Systems · PMA 2023
- Silicone Stimulation Lead, Silicone Sensing LeadInspire Medical Systems · PMA 2022
- Inspire Medical Systems, Model 2580 Patient ProgrammerInspire Medical Systems · PMA 2021
- Inspire Programmer SystemInspire Medical Systems · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.